Table 2. Determination of End of Treatment Values for Placebo and “Curcumin” Treatmenta Groups from COPD Subjects.
| baselineb |
percent
change, %b |
end
of treatmentc |
||||
|---|---|---|---|---|---|---|
| parameter | placebo | treatment | placebo | treatment | placebo | treatment |
| BMI, kg/m2 | 24.4 | 22.1 | –0.7 | 0.9 | 24.2 | 22.3 |
| SBP, mmHg | 127.7 | 127.6 | 1.4 | –1.3 | 129.5 | 125.9 |
| DBP, mmHg | 70.5 | 70.7 | 2.9 | 3.5 | 72.5 | 73.2 |
| HbA1c, % | 5.3 | 5.4 | 0.0 | 0.4 | 5.3 | 5.4 |
| BS, mg/dL | 98.6 | 102.8 | 14.5 | 5.8 | 112.9 | 108.8 |
| TG, mg/dL | 160.1 | 146.3 | 14.5 | 9.2 | 183.3 | 159.8 |
| LDL-C, mg/dL | 104.5 | 106.8 | 11.4 | 4.6 | 116.4 | 111.7 |
| HDL-C, mg/dL | 60.1 | 62.1 | 2.0 | –2.8 | 61.3 | 60.4 |
| UA, mg/dL | 6.2 | 6.6 | 2.3 | 2.4 | 6.3 | 6.8 |
| γ-GTP, IU/L | 39.8 | 52.3 | –1.2 | –5.7 | 39.3 | 49.3 |
| Cre, mg/dL | 1.0 | 0.9 | 1.4 | 2.9 | 1.0 | 0.9 |
| CRP, mg/dL | 0.2 | 0.3 | 11.1 | –12.5 | 0.2 | 0.3 |
| SAA-LDL, μg/mL | 8.9 | 14 | 10.8 | –2.0 | 9.9 | 13.7 |
| AT-LDL, μg/mL | 1.2 | 1.4 | 14.8 | –1.6 | 1.4 | 1.4 |
| FEV1, % | 64.7 | 61.9 | –3.6 | –1.9 | 62.4 | 60.7 |
a
See main text for comments on the intervention agent.
b
Reported in Funamoto et al.4
c
Calculated using the given baseline data and reported percent change for each value.